August 22, 2008 (FinancialWire) Bioheart, Inc., (NASDAQ: BHRT) (Current Market Cap: US$59.23 Mil.) said it has received a $1 million unsecured loan from Rogers Telecommunications Ltd.

Bioheart, Inc., (Nasdaq: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced receipt of a $1 million unsecured loan from Rogers Telecommunications Limited. This loan is payable upon the later of three months or Bioheart's repayment of its loan from BlueCrest Capital. In addition, under certain circumstances, the Company may be permitted to pay outstanding interest and principal in shares of its common stock. The loan will be used for Bioheart's ongoing clinical and business operations, as the Company continues to actively pursue additional investment support.

Company representatives of Bioheart Inc (NasdaqSC: BHRT) will be presenting at the RedChip Emerging Markets Small-Cap Investor Conference today. The Company's presentation is scheduled to begin at 09:30 ET.

Bioheart Inc (Nasdaq: BHRT), which is focused on development of solutions and systems for signal and data processing in cardiac monitoring, heart sounds and electrophysiology of the heart, declared on 1 August that it has signed a non-binding letter of intent to acquire MEDICALGORITHMICS Ltd as well as the worldwide rights to the POCKETECG. The two companies, following the terms of the non-binding letter of intent, are anticipated to conduct their due diligence review within the next 60-90 days. The terms of the agreement were not released. According to Bioheart Inc, POCKETECG is a real-time wireless beat-to-beat, intelligent heart monitor and diagnostic system, designed for long-term, fully-automated electrocardiogram (ECG) arrhythmia analysis.

Bioheart, Inc. (Nasdaq: BHRT) today announced that Howard J. Leonhardt, Chairman and CEO of Bioheart, will present a corporate overview Thursday, August 21, 2008 at 9:30 a.m. ET during the Red Chip Investor Conference at the Marriott Marquis in New York. A live audio webcast and slide presentation will be available via the internet by visiting and registering to attend at: http://www.redchip.com.

Bioheart, Inc., (Nasdaq: BHRT), announced it has entered into a non-binding letter of intent to acquire MEDICALGORITHMICS, Ltd. and the worldwide rights to the POCKETECG, a real-time wireless beat-to-beat, intelligent heart monitor and diagnostic system, designed for long-term, fully-automated electrocardiogram (ECG) arrhythmia analysis. The device, manufactured by MEDICALGORITHMICS, Ltd., Poland, recently received CE mark approval for marketing throughout Europe.

Bioheart, Inc., (Nasdaq: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, announced the adoption of the following resolutions during today's Annual Shareholders Meeting:

Bioheart, Inc., (Nasdaq: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced financial results for the second quarter ended June 30, 2008.

Results of a preclinical study involving the injection of myoblasts modified to express stromal derived factor-1(alpha) protein (SDF-1) into the scar tissue of the myocardium of rats, which suggest improved heart function, were recently presented at two scientific meetings -- the International Society for Magnetic Resonance in Medicine (ISMRM) in Toronto, and the American Society of Gene Therapy Meeting (ASGT) in Boston.

Bioheart Inc (Nasdaq: BHRT), a provider of devices and biologics which helps monitor, diagnose and treat heart failure and cardiovascular diseases, reported on 11 July that the company has been awarded worldwide non-exclusive distribution rights to the Bioheart 3370 Heart Failure Monitor. The product will be launched with immediate effect through physician prescription. The Bioheart 3370 Heart Failure Monitor is an interactive and simple-to-use at-home intelligent device designed specifically to improve available healthcare to patients, outside hospitals, who are suffering from heart failure. The device engages patients through personalised daily interactions and questions, while collecting vital signs and transmitting the information directly into a database. It is uniquely available in both a wireless configuration and through hook-up to regular telephone lines. The data is regularly monitored by a remotely located medical professional and reported back to the treating physician. Reportedly, the Bioheart 3370 Heart Failure Monitor is manufactured by RTX Healthcare A/S (Denmark) and has 510k market clearance from the US Food and Drug Administration for marketing in the US and CE mark approval for marketing in Europe and other countries. The Bioheart 3370 At-Home Heart Failure Monitor aims to significantly reduce the number of emergency hospitalisation days, as well as their associated costs. Congestive heart failure (CHF), or heart failure, is a condition in which the heart can't pump enough blood to the body's other organs. Heart failure is a leading cause of hospitalisation in people over age 65.

Stocks in the News: Hybred International, Inc., (PINKSHEETS: HYII), Eddie Bauer, Inc. (NASDAQ: EBHI), NeurogesX, Inc. (NASDAQ: NGSX), Bioheart, Inc. (NASDAQ: BHRT)

July 14, 2008 (FinancialWire) Bioheart, Inc., (NASDAQ: BHRT) (Current Market Cap: US$54.61 Mil.) said that Doug Owens, its director of clinical affairs, will assume responsibility for Bioheart's regulatory and clinical strategy for its investigational MyoCell Therapy clinical trials from Richard T. Spencer, IV, who served as Bioheart's VP of clinical affairs and physician relations.

Bioheart, Inc., (Nasdaq: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, announced today that Doug Owens, Director, Clinical Affairs, will assume responsibility for Bioheart's regulatory and clinical strategy for its investigational MyoCell(R) Therapy clinical trials from Richard T. Spencer, IV, who served as Bioheart's Vice President, Clinical Affairs and Physician Relations. Spencer has decided to leave Bioheart to pursue other opportunities, but has agreed to be available through the end of August to consult with Bioheart on the sale and distribution of the Bioheart 3370 Heart Failure Monitor as well as ongoing clinical trial activities.

Expands Focus to Include Intelligent Devices in Treatment of Heart Failure and Cardiovascular Diseases

By Fain Hughes, fhughes@knobias.com

Bioheart, Inc. (Nasdaq: BHRT), a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced it has secured worldwide non-exclusive distribution rights to the Bioheart 3370 Heart Failure Monitor, an interactive and simple-to-use at-home intelligent device designed specifically to improve available healthcare to patients outside hospitals who are suffering from heart failure. The device, manufactured by RTX Healthcare A/S (Denmark), has 510k market clearance from the US Food and Drug Administration for marketing in the U.S. and CE mark approval for marketing in Europe and other countries that follow this mark. The Company is planning to begin immediate commercial distribution.

The board of directors of Bioheart Inc (Nasdaq: BHRT), a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, declared on 3 July that Howard J Leonhardt has been hired as chief executive officer of the company, with effect from 1 July 2008.

Bioheart Inc. on Thursday named Howard Leonhardt as chief executive, effective July 1.

Bioheart, Inc., (Nasdaq: BHRT) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today announced that its Board of Directors appointed Howard J. Leonhardt, Bioheart's co-founder, Chairman of the Board and Chief Technology Officer, to serve as Chief Executive Officer effective as of July 1, 2008. This follows the resignation of William M. Pinon as the Company's President and CEO and as a member of the Board of Directors as of the same date. Pinon has agreed to remain with the Company through July 25, 2008 to assist in the executive transition process.

Bioheart, Inc. (Nasdaq: BHRT) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today announced it has been added to the Russell Microcap Index after the Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes on June 27, 2008.

By Fain Hughes, fhughes@knobias.com

Bioheart, Inc. (Nasdaq: BHRT) today announced that it has received approval to transfer the listing of its common stock to the Nasdaq Capital Market. The Company's common stock will be transferred from The Nasdaq Global Market to The Nasdaq Capital Market at the opening of business on Wednesday, June 11, 2008. The Nasdaq Capital Market is a tier of the Nasdaq Stock Market for companies with a lower market capitalization requirement than the Global Market tier. The Company's stock will continue to trade, and benefit from the liquidity provided by the Nasdaq Stock Market.

Bioheart, Inc. (Nasdaq: BHRT) will host its 2008 Annual Meeting of Shareholders on Wednesday, July 30, 2008 at Chispa Restaurant, located at 11500 NW 41st Street in Doral, Florida. The meeting will commence at 9:00 am EASTERN.